J&J to Spin Off Orthopedics Business, Raises 2025 Forecast

Johnson & Johnson (J&J) has announced plans to separate its orthopedics unit into a standalone company, while simultaneously raising its 2025 full-year sales guidance. 

Key Points

• The orthopedics division, which manufactures hip, knee, and shoulder implants, surgical instruments, and related products, generated about USD 9.2 billion last year — roughly 10% of J&J’s total revenue. 

• J&J now expects product revenue of USD 93.5–93.9 billion in 2025, a USD 300 million upward revision from its prior forecast — and above analysts’ average estimate of USD 93.4 billion. 

• The company intends to spin off the unit under the name DePuy Synthes within the next 18 to 24 months. 

• Although the orthopedics business is profitable, J&J’s leadership explained that the next phase of innovation in orthopedics lies outside the core strengths of J&J’s new strategic focus. 

• J&J’s Chief Financial Officer indicated that a tax-free spin-off is being explored, though alternative structural options remain under consideration. 

• The move follows J&J’s earlier major spin-off — the separation of its consumer health business into Kenvue — reflecting a broader shift toward a more focused portfolio. 

Implications & Strategic Rationale 

1. Sharpened Focus on Core Businesses

   By spinning off orthopedics, J&J can concentrate on high-growth sectors such as oncology, immunology, neuroscience, surgery, vision, and cardiovascular. 

2. Unlocking Shareholder Value

   As a stand-alone entity, DePuy Synthes may attract investors who specialize in medtech or implant businesses, potentially boosting valuation multiple.

3. Flexibility for Innovation & Partnerships

   Freed from the oversight of a conglomerate structure, the new orthopedics company could pursue alliances, joint ventures, targeted R&D, or M&A more agilely.

4. Regulatory & Tax Optimization

   A tax-free spin-off would help J&J realize separation without excessive fiscal burden, though structuring and regulatory approval will be critical.

5. Market Reaction

   The announcement was met positively: J&J’s shares climbed nearly 2% in premarket trading on the news.